Vicero Bio
Preclinical-stage biopharmaceutical company developing modular VHH (single-domain antibody) multivalent therapeutics engineered to enable multi-target immuno-oncology combinations and multi-payload antibody-drug conjugates with improved safety, tumor penetration, and subcutaneous dosing.
Industries
Nr. of Employees
small (1-50)
Products
Lead bispecific PD-1 + CTLA-4 VHH therapeutic (preclinical candidate)
Preclinical multivalent single-domain antibody candidate designed to neutralize PD-1 and CTLA-4 on a single scaffold, showing robust preclinical efficacy and reduced immune-related toxicity in animal models.
Dual/multi-payload ADC candidates (preclinical)
Preclinical antibody-drug conjugate candidates using compact multivalent scaffolds to enable dual or multiple payload delivery for improved tumor targeting and payload efficacy.
VCR-036
A bi-specific PD-1 + CTLA-4 VINCOBODY designed to deliver the efficacy of combination therapy without safety trade-offs.
VINCOBODIES
Small, modular medicines designed to deliver the strength of combination cancer treatment with fewer trade-offs, enabling engagement of multiple targets or payloads in one medicine.
VINCOBODY platform
A proprietary technology platform focused on multi-specific immuno-oncology and multi-payload antibody-drug conjugates.
VCR-018
Dual and multi-payload ADC candidate targeting LY75/CD205 designed to overcome limitations in tumor targeting and payload delivery.
Lead bispecific PD-1 + CTLA-4 VHH therapeutic (preclinical candidate)
Preclinical multivalent single-domain antibody candidate designed to neutralize PD-1 and CTLA-4 on a single scaffold, showing robust preclinical efficacy and reduced immune-related toxicity in animal models.
Dual/multi-payload ADC candidates (preclinical)
Preclinical antibody-drug conjugate candidates using compact multivalent scaffolds to enable dual or multiple payload delivery for improved tumor targeting and payload efficacy.
VCR-036
A bi-specific PD-1 + CTLA-4 VINCOBODY designed to deliver the efficacy of combination therapy without safety trade-offs.
VINCOBODIES
Small, modular medicines designed to deliver the strength of combination cancer treatment with fewer trade-offs, enabling engagement of multiple targets or payloads in one medicine.
VINCOBODY platform
A proprietary technology platform focused on multi-specific immuno-oncology and multi-payload antibody-drug conjugates.
VCR-018
Dual and multi-payload ADC candidate targeting LY75/CD205 designed to overcome limitations in tumor targeting and payload delivery.
Services
Collaborative partnerships for discovery, target evaluation, and co-development of multispecific IO and ADC programs.
Collaborative partnerships for discovery, target evaluation, and co-development of multispecific IO and ADC programs.
Expertise Areas
- Multispecific antibody engineering
- VHH / single-domain antibody therapeutics
- Antibody-drug conjugate (ADC) development
- Preclinical pharmacology and toxicology
Key Technologies
- VHH (single-domain antibody) engineering
- Multispecific / bispecific antibody design
- Antibody-drug conjugation
- In vivo tumor models and pharmacology
News & Updates
Poster presentation of preclinical data for the lead bispecific PD-1/CTLA-4 VHH candidate at the inaugural AACR Immuno-Oncology meeting (abstract and poster available).
Press release describing preclinical safety and efficacy data for the pentavalent PD-1/CTLA-4 single-domain antibody candidate, including survival, tumor regression, and PK supporting projected low-dose subcutaneous regimens.
Press release announcing appointment of a Chief Medical Officer to lead clinical strategy and execution for the multivalent VHH pipeline and to advance the lead program toward IND-enabling studies and clinical development.
Press release announcing additions of clinical and translational immuno-oncology experts to the Scientific Advisory Board to guide platform and clinical strategy.
Preclinical data for the lead bispecific VHH candidate selected as a late-breaker poster at the inaugural AACR Immuno-Oncology conference.
Poster presentation of preclinical data for the lead bispecific PD-1/CTLA-4 VHH candidate at the inaugural AACR Immuno-Oncology meeting (abstract and poster available).
Press release describing preclinical safety and efficacy data for the pentavalent PD-1/CTLA-4 single-domain antibody candidate, including survival, tumor regression, and PK supporting projected low-dose subcutaneous regimens.
Press release announcing appointment of a Chief Medical Officer to lead clinical strategy and execution for the multivalent VHH pipeline and to advance the lead program toward IND-enabling studies and clinical development.
Press release announcing additions of clinical and translational immuno-oncology experts to the Scientific Advisory Board to guide platform and clinical strategy.
Preclinical data for the lead bispecific VHH candidate selected as a late-breaker poster at the inaugural AACR Immuno-Oncology conference.